Biotechnology

OS Therapies

Jason McCarthy Maintains Buy Rating for OS Therapies Incorporated

OS Therapies Launches Cancer Immunotherapy Pipeline and Plans for Accelerated Approval

OS Therapies Inc. preparing regulatory meetings with MHRA and FDA to discuss drug development plans

OS Therapies released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -0.5783

OS Therapies released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2152 (forecast USD -0.125)

OS Therapies Announces Recent Advances in Cancer Immunotherapy and Plans for Accelerated Approval of OST-HER2

OS Therapies Inc. Receives Positive Regulatory Update Following EMA Meeting

OS Therapies Inc. Plans to Submit OST-HER2 Regulatory Application

OS Therapies released FY2025 Q2 earnings on August 18, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD -0.1806 (forecast USD -0.1033)

OS Therapies released FY2025 Semi-Annual Earnings on August 18, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.3357

Biopharmaceutical Company OS Therapies to Release Quarterly Earnings

OS Therapies Inc. Plans to Apply for OST-HER2 Biologics License Application

OS Therapies Receives FDA Notification for OST-HER2 Phase 2 End of Meeting

OST-HER2 Receives Positive Feedback from FDA

OS Therapies Inc. selects EVERSANA® as global commercial services partner

OS Therapies Submits RMAT Certification Application to FDA

OS Therapies Inc. Highlights Positive Data from OST-HER2 Phase 2b Trial

OS Therapies released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1824 (forecast USD -0.075)

OS Therapies Inc. Launches Subsidiary for Veterinary Oncology

Shalom Auerbach Sells Shares of OS Therapies Inc.

Republic Power

Brand Engagement Network

Society Pass

Intelligent Living Application

3 E Network Tech

Globavend

CCSC Tech

Sidus Space

Tryhard

Dreamland

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap